- IRADIMED reported third quarter 2026 sales of US$24.2 million and net income of US$6.51 million, with basic and diluted earnings per share of US$0.51 from continuing operations. The company also declared a regular quarterly dividend of US$0.20 per share payable on November 27, 2026.
- The combination of rising year on year sales and earnings, ongoing dividend payments, and forward guidance on revenue and GAAP diluted EPS gives investors more concrete data on how IRADIMED balances growth investments with current profitability and cash returns.
- The next step is to consider how IRADIMED's earnings guidance and dividend decision could influence the investment narrative already built around its MRI focus.
Scan beyond IRADIMED's latest quarter and compare its mix of earnings strength and dividends with a hand picked list of solid balance sheet and fundamentals (24 results) in similar financially resilient businesses.
IRADIMED Investment Narrative Recap
To own IRADIMED, you need to believe its tight focus on MRI compatible pumps and monitors remains an advantage rather than a cap. The third quarter numbers and full year guidance point to a business that is still leaning on the 3870 pump rollout and MRI monitoring to drive top line and keep profitability intact.
The key short term swing factor is how efficiently IRADIMED runs 3870 production while meeting demand in both replacement and new accounts. Any prolonged manufacturing inefficiency or softer order flow into the fourth quarter would hit margins first. The latest results and guidance inform expectations but do not remove that operational risk.
The fresh full year 2026 guidance is most relevant for you as an investor. Management now expects revenue between US$91.6 million and US$93.1 million and GAAP diluted EPS of US$1.90 to US$1.94. That range anchors near term expectations around how much of today’s MRI pump and monitor momentum can translate into earnings.
This outlook matters because it frames the payoff from the 3870 replacement cycle and the mix shift toward higher priced quad systems. At the same time, gross margin is still sensitive to manufacturing efficiency. If results land meaningfully outside that band, the market reaction could be sharp given IRADIMED’s higher P/E and concentration in a single product category.
IRADIMED's consensus narrative points to forecast revenue of US$119.9 million and projected earnings of US$34.9 million by 2029, which implies 11.6% yearly revenue growth and an earnings increase of US$11.8 million from current earnings of US$23.1 million.
Uncover how IRADIMED's fair value indicates a 37% potential upside to its current price, which could narrow quickly if IRADIMED keeps executing against this guidance band.
Exploring Other Perspectives
Fair value estimates for IRADIMED from 2 private investors in the Simply Wall St Community span roughly US$79.79 to US$118, so opinions already stretch from cautious to optimistic. Set that against concentration in MRI specific hardware and ongoing 3870 ramp risks, and you get real dispersion. Explore those alternate views before anchoring on one story.
Explore another IRADIMED fair value estimate, including one that suggests as much as 37% potential upside from the current price.
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your IRADIMED research is our analysis highlighting 2 key rewards that could impact your investment decision.
- See our latest analysis for IRADIMED. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate IRADIMED's overall financial health at a glance.
Looking For More IRADIMED-Sized Investment Ideas?
Once you have a view on IRADIMED, broaden your watchlist with other stocks that match the kind of balance between quality, income, and resilience you are looking for using the Simply Wall St Screener.
- If you want companies that combine staying power with measured risk, start with a focused set of 29 resilient stocks with low risk scores that may help anchor the defensive side of your portfolio.
- For investors who care most about strong financial footing and robust fundamentals, compare IRADIMED against a broader list of solid balance sheet and fundamentals (24 results) to see how it stacks up on balance sheet strength.
- When you are hunting for potential future leaders that are not heavily followed yet, scan a curated pool of 19 high quality undiscovered gems that share similar quality traits but fly under most radars.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com